‍

Stuart Lowe, Head of Advanced Therapies at TTP, will be speaking at Phacilitate Advanced Therapies Week 2025. Join Stuart on January 22, 2025, at 16:00 at the Kay Bailey Hutchison Convention Center, Dallas, TX.

‍

Accelerating the development of cell and gene therapies – the ‘why’ and the ‘how’

The cell and gene therapy industry is at a crossroads. Are these incredible therapies going to be mass market cures or only accessible to a chosen few? And can the needs of patients drive development decisions well before reaching the clinic?

Therapy developers face a challenge balancing demonstrating clinical progress in the short-to-medium term alongside planning for future scale-up capacity. Introducing process automation at an early stage provides several benefits including: reduction of handling variability, improvement in facility utilisation, and shorter transfer to commercial manufacture.

In this talk find out how TTP has helped companies to implement targeted process automation, deploying a systematic approach that focuses on single process steps, identifying suitable hardware (and/or custom hardware development), and considering scalability alongside PD goals.

‍

About Advanced Therapies Week

Phacilitate Advanced Therapies Week 2025 is the leading global event for the cell and gene therapy, regenerative medicine, and tissue engineering sectors. Held in Dallas, TX, from January 20-24, 2025, the conference serves as a hub for collaboration and innovation, uniting key players to address the critical challenges of therapy development and commercialization. With a focus on advancing the field, attendees will engage in insightful discussions, explore breakthrough technologies, and connect with industry leaders driving the future of advanced therapies.

‍

About our Advanced Therapies Team

TTP, as a specialist hardware and technology developer for the cell and gene therapy industry, has been working with the industry for over 20 years to create de novo solutions to improve cellular bioprocessing. The work we do helps enable therapy developers to commercialise emerging modalities where there is often less choice in off-the-shelf bioprocess equipment.

Join Stuart on this talk to find out how TTP has helped companies to implement targeted process automation, deploying a systematic approach that focuses on single process steps, identifying suitable hardware (and/or custom hardware development), and considering scalability alongside PD goals.